Skip to main content

Table 15 Benchmarking of antimicrobial resistance rates in this report against the report of the International Nosocomial Infection Control Consortium (2007–20012) and the report of the US National Healthcare Safety Network Data (2009–2010)

From: International Nosocomial Infection Control Consortium (INICC) national report on device-associated infection rates in 19 cities of Turkey, data summary for 2003–2012

 

This report resistance %

INICC 2007–2012 resistance %

NHSN 2009–2010 resistance, %

Pathogen, antimicrobial

(CLABSI)

(CLABSI)

(CLABSI)

Staphylococcus aureus

   

Oxacillin

92.7%

61.2%

54.6%

Enterococcus faecalis

   

Vancomycin

5.0%

12.2%

9.5%

Pseudomonas aeruginosa

   

Ciprofloxacine

35.3%

37.5%

30.5%

Piperacillin or piperacillin-tazobactam

27.6%

33.5%

17.4%

Amikacin

18.9%

42.8%

10.0%

Imipenem or meropenem

37.1%

42.4%

26.1%

Klebsiella pneumoniae

   

Ceftriaxone or ceftazidime

55.7%

71.2%

28.8%

Imipenem or meropenem

6.3%

19.6%

12.8%

Acinetobacter baumanii

   

Imipenem or meropenem

56.1%

66.3%

62.6%

Escherichia Coli

   

Ceftriaxone or ceftazidime

55.2%

65.9%

19.0%

Imipenem or meropenem

4.4%

8.5%

1.9%

Ciprofloxacine

66.2%

69.3%

41.8%

  1. CLABSI, central line-associated bloodstream infection.